Premium
Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LC–MS/MS for doping controls
Author(s) -
Thomas Andreas,
Krombholz Sophia,
Wolf Carina,
Thevis Mario
Publication year - 2021
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.3176
Subject(s) - ghrelin , urine , chemistry , chromatography , endocrinology , medicine , hormone , biochemistry
The hunger hormone ghrelin (G) is classified as prohibited substance in professional sport by the World Anti‐Doping Agency (WADA), due to its known growth hormone releasing properties. The endogenous bioactive peptide consists of 28 amino acids with a caprylic acid attached to serine at position 3. Within this study, it was aimed to develop methods to determine G and desacyl ghrelin (DAG) in plasma and urine by means of LC–MS/MS. Two strategies were applied with a bottom‐up approach for plasma and top‐down analyses for urine. Both sample preparation procedures were based on solid‐phase extraction for enrichment and sample clean‐up. Method validation showed good results for plasma and urine with limits of detection (LODs) for G and DAG between 30 and 50 pg/ml, recoveries between 45–50%, and imprecisions (intra‐ and inter‐day) between 3% and 24%. Plasma analysis was also valid for quantification with accuracies determined with ~100% for G and ~106% for DAG. The minimum required performance level for doping control laboratories is set to 2 ng/ml in urine, and the herein established method yielded acceptable results even at 5% of this level. As proof‐of‐concept, plasma levels (G and DAG) of healthy volunteers were determined and ranged between 30 and 100 pg/ml for G and 100–1200 pg/ml for DAG. In contrast to earlier reported studies using ligand binding assays for urinary G and DAG, in this mass spectrometry‐based study, no endogenous urinary G and DAG were found, although the LODs should enable this.